יוקריאס 50/850 מ"ג Israel - Tiếng Do Thái - Ministry of Health

יוקריאס 50/850 מ"ג

novartis pharma services ag - metformin hydrochloride 850 mg; vildagliptin 50 mg - film coated tablets - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus:• eucreas is indicated in the treatment of type 2 diabetes patients who are unable to achieve sufficient glycemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.• eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulphonylurea.• eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.

נובוגרד 1 מ"ג/500 מ"ג Israel - Tiếng Do Thái - Ministry of Health

נובוגרד 1 מ"ג/500 מ"ג

novo nordisk ltd - metformin hydrochloride 500 mg; repaglinide 1 mg - tablets - metformin - novogard is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 mellitus who are already treated with a meglitinide and metformin hcl or who have inadequate glycemic control on a meglitinide alone or metformin hcl alone.

נובוגרד 2 מ"ג/500 מ"ג Israel - Tiếng Do Thái - Ministry of Health

נובוגרד 2 מ"ג/500 מ"ג

novo nordisk ltd - metformin hydrochloride 500 mg; repaglinide 2 mg - tablets - metformin - novogard is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 mellitus who are already treated with a meglitinide and metformin hcl or who have inadequate glycemic control on a meglitinide alone or metformin hcl alone.

יוקריאס 50/500 מ"ג Israel - Tiếng Do Thái - Ministry of Health

יוקריאס 50/500 מ"ג

novartis pharma services ag - metformin hydrochloride 500 mg; vildagliptin 50 mg - film coated tablets - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.

טרג'נטה דואו 2.5 מג500 מג Israel - Tiếng Do Thái - Ministry of Health

טרג'נטה דואו 2.5 מג500 מג

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - טבליות מצופות פילם - metformin hydrochloride 500 mg; linagliptin 2.5 mg - metformin - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.

טרג'נטה דואו 2.5 מג850  מג Israel - Tiếng Do Thái - Ministry of Health

טרג'נטה דואו 2.5 מג850 מג

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - טבליות מצופות פילם - metformin hydrochloride 850 mg; linagliptin 2.5 mg - metformin - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.

טרג'נטה דואו 2.5 מג1000 מג Israel - Tiếng Do Thái - Ministry of Health

טרג'נטה דואו 2.5 מג1000 מג

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - טבליות מצופות פילם - linagliptin 2.5 mg; metformin hydrochloride 1000 mg - metformin - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.

קומפטקט 15 מג  850 מג Israel - Tiếng Do Thái - Ministry of Health

קומפטקט 15 מג 850 מג

tzamal bio-pharma ltd - metformin hydrochloride; pioglitazone as hydrochloride - טבליות מצופות פילם - metformin hydrochloride 850 mg; pioglitazone as hydrochloride 15 mg - metformin - metformin - competact is indicated as second line treatment of type 2 diabetes mellitus adult patients,particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

גלוקומין Israel - Tiếng Do Thái - Ministry of Health

גלוקומין

dexcel ltd, israel - metformin hydrochloride - קפליות - metformin hydrochloride 850 mg - metformin

גלוקופג' Israel - Tiếng Do Thái - Ministry of Health

גלוקופג'

abic ltd. - metformin hydrochloride - קפליות - metformin hydrochloride 850 mg - metformin